



ThermoFisher
S C I E N T I F I C



Analytical Strategies for Studying Glycosylation of Biopharmaceuticals

Joachim Weiss, D.Sc.
International Technical Director
Vendor Seminar, ISC 2016, Cork, Ireland

- Introduction
- Glycan workflows
 - Monosaccharides and sialic acids
 - Labeled glycans
 - Labeled glycans – high throughput
 - Unlabeled glycans
 - Glycopeptides
 - Intact glycoproteins
- Conclusions

What Role do Glycans Play in Biotherapeutics?


- **70%** of protein drug candidates in clinical development are glycosylated
- Many host-pathogen interactions occur using glycans (recognition, degradation, etc.)
- Glycosylation affects:
 - Biological activity
 - Pharmacokinetics
 - Stability
 - Immunogenicity
- Glycosylation is the most common post-translational modification (PTM) studied in biopharmaceuticals




Characterization and Confirmation of Biological Products

ICH (Q6B) recommended six test approaches for characterization and confirmation of biological products:


- Amino acid sequence
- Amino acid composition
- Terminal amino acid sequence
- Peptide map
- Sulfhydryl group(s) and disulfide bridges
- **Carbohydrate structure**
 - *“For glycoproteins, the carbohydrate content and structure (neutral sugars, amino sugars, and sialic acids) is determined.”*




Glycan Workflows




Monosaccharides & Sialic Acids




Labeled Glycans




Labeled Glycans – High throughput



Unlabeled Glycans




Glycopeptides



Intact Glycoprotein


Monosaccharides & Sialic Acids



Monosaccharide Analysis Workflow



Glycoprotein




Monosaccharides




HPAE-PAD

- Monosaccharide composition can screen for changes in glycosylation
- Allows measurement of **total sugars** and amounts of specific **monosaccharides**
- Workflow using **HPAE-PAD** (anion-exchange chromatography) – specific carbohydrate chromatography and detection

HPAE-PAD Glycoprotein Monosaccharide Systems



Monosaccharide Compositional Analysis of Human IgG



Column: Thermo Scientific™ Dionex™ CarboPac™ PA 20
 Dimensions: 150 mm × 0.4 mm i.d.
 Temperature: 30 ° C
 Eluent: KOH (EG)
 Gradient: 12 mmol/L for 15 min, then to 100 mmol/L for 15 min
 Flow rate: 9 µL/min
 Inj. volume: 0.4 µL
 Detection: IPAD (carbohydrate quadruple waveform) on a gold electrode
 Sample: Standards (10 µM)

- Peaks:
1. Fucose
 2. Deoxyglucose (internal standard)
 3. Galactosamine
 4. Glucosamine
 5. Galactose
 6. Glucose
 7. Mannose
- * Amino acids

Sialic Acid Analysis Workflow

- Sialic acids are released from glycoproteins by either mild acid hydrolysis or by treatment with a neuraminidase
- Samples are then dried to remove the acid
- Samples are injected onto the HPAE-PAD system
- For neuraminidase digestions the sample is either injected or diluted and injected

Traditional Gradient Separation of Glycoprotein Hydrolysates


Column: Dionex CarboPac PA20 with guard
 Dimensions: 150 mm × 3 mm i.d.
 Eluent: 70-300 mmol/L NaOAc in 100 mmol/L NaOH from 0-7.5 min, 300 mmol/L NaOAc in 100 mmol/L NaOH from 7.5-9.0 min

Temperature: 30°C
 Flow rate: 0.5 mL/min
 Inj. volume: 10 µL
 Detection: IPAD, disposable Au electrode

Samples: (A) b. apo-transferrin, (B) h. transferrin, (C) fetuin, (D) s. α_1 -acid glycoprotein, (E) h. α_1 -acid glycoprotein


Sample prep: Acid hydrolysis followed by lyophilization and dissolution

Peaks:	(A)	(B)	(C)	(D)	(E)
1. Neu5Ac	1.7	4.4	18	15	37 pmol
2. Neu5Gc	2.1	ND	0.4	2.6	ND



A 10% signal offset has been applied.
 ND = Not Detected


Rapid Isocratic Separation of Sialic Acids




Column: Dionex CarboPac SA10
Dimensions: 250 mm × 4 mm i.d.
Eluent: 0.2 mol/L NaOH
Flow rate: 1.5 mL/min
Inj. volume: 10 μ L
Detection: IPAD, Au electrode

Sample: 1. *N*-acetylneuraminic acid 50 μ mol
2. *N*-glycolylneuraminic acid 50

Labeled Glycans




Labeled Glycans – Quantification and Qualification




- Glycan-specific separations:
 - Thermo Scientific™ GlycanPac™ AXH-1
 - Thermo Scientific™ GlycanPac™ AXR-1
 - Thermo Scientific™ Accucore™ 150-Amide-HILIC
- Trace **quantification using new fluorescence detector** for Thermo Scientific™ Vanquish™ Flex UHPLC
- Qualitative **released glycan structure analysis** can be confirmed using HRAM MS and SimGlycan® software (PREMIER Biosoft)

HILIC Separation of 2AB Labeled Glycans from Human IgG



Column: Accucore 150 Amide HILIC 2.6 μ m
Dimensions: 150 mm \times 2.1 mm i.d.
Temperature: 50 $^{\circ}$ C, still air
Eluent: A. MeCN
B. 50 mmol/L ammonium formate, pH 4.4
Gradient: 0-30 min from 20 to 42% B,
30-30.5 min to 50% B, 30.5-32 min
50% B, 32-32.5 min to 20% B,
32.5-60 min 20% B (equilibration)
Flow rate: 400 μ L/min
Pressure: 210 bar (max.)
Inj. volume: 5 μ L
Detection: Fluorescence
Excitation wavelength: 320 nm
Emission wavelength: 420 nm
Lamp mode: HighPower
Sensitivity: 8
Data collection rate: 5 Hz
Response time: 1 s
Sample: 1 nmol/mL 2-AB labeled *N*-glycans
Immunoglobulin G library

Charge-based/HILIC Separation on GlycanPac AXH-1




Peak	Glycan Type	Relative %
1	Neutral	0.4
2	MonoSialic	8.6
3	DiSialic	38.4
4	TriSialic	45.4
5	TetraSialic	7.0
6	PentaSialic	0.2

Column: **GlycanPac AXH-1 (1.9 μm)**
 Dimension: 2.1 × 150 mm
 Mobile Phase A: Acetonitrile
 Mobile Phase B: Ammonium formate (50 mM, pH = 4.4)
 Mobile Phase C: Water

Time (min)	% A	% B	% C	Flow (mL/min)
-5	90	10	0	0.4
0	90	10	0	0.4
6	50	20	30	0.4
12	50	20	30	0.4

Flow Rate: 0.4 mL/min
 Injection Volume: 40 pmole
 Temperature: 30 °C
 Detection: Fluorescence at 320/420 nm
 Sample: 2AB Labeled *N*-glycans from bovine fetuin

After enzymatic digestion with sialidase S and sialidase A




Column: **GlycanPac AXH-1 (1.9 μm)**
 Dimension: 2.1 × 150 mm
 Mobile Phase A: Acetonitrile (100%)
 Mobile Phase B: Water
 Mobile Phase C: Ammonium formate (100 mM, pH = 4.4)
 Flow Rate: 0.4 mL/min
 Injection Volume: 50 Pmoles
 Temperature: 30 °C
 Detection: Fluorescence at 320/420 nm
 Sample: 2AB labeled *N*-glycan from bovine fetuin

Time (min)	% A	% B	% C	Flow (mL/min)	Curve
-10	78	20	2	0.4	5
0	78	20	2	0.4	5
30	70	20	10	0.4	5
35	60	20	20	0.4	5
40	50	20	30	0.4	5

Separation based on charge, size, and shape

Charged-based/RP Separation on GlycanPac AXR-1


- WAX functionality: separates glycans into different “clusters” in order of increasing charge
- RP functionality: facilitates further separation within each “cluster” to achieve high-resolution separations for glycans of the same charge according to their **isomerism** and **size**




~ 80 resolved peaks

Selectivity Comparison of GlycanPac and Amide HILIC columns


GlycanPac AXR-1 (1.9 μm)
(>100 peaks resolved)



GlycanPac AXH-1 (1.9 μm)
(>60 peaks resolved)





Amide HILIC (1.7 μm)
(>40 peaks resolved)





When to use which column?


EPO




Therapeutic Antibodies



2AA Labeled N-Glycans from Human IgG



Column: GlycanPac AXH-1, 1.9 μ m
Dimensions: 150 mm \times 2.1 mm i.d.
Temperature: 30 $^{\circ}$ C
Eluent: A. MeCN/water (80:20 v/v)
 B. 80 mmol/L ammonium formate, pH 4.4
Gradient: 1% B to 12.5% B in 30 min
Flow rate: 0.4 mL/min
Injection: 20 pmoles
Detection: Fluorescence
 Excitation wavelength: 320 nm
 Emission wavelength: 420 nm
Sample: 2-AA labeled N-glycans from human IgG




- N-Acetyl glucosamine (GlcNAc)
- Mannose (Man)
- Galactose (Gal)
- ◆ N-Acetyl neuraminic acid (Neu6Ac)
- ▼ L-Fucose (L-Fuc)

Peak	Structure	Charge of Glycan (without 2AA label)	Molecular Mass (including 2AA label)
1		0	1380.5176
2		0	1437.5262
3		0	1503.5672
4		0	1542.5736
5		0	1542.5736
6		0	1586.5821
7		0	1745.6200
8		0	1745.6200
9	Unknown		Unknown

Peak	Structure	Charge of Glycan (without 2AA label)	Molecular Mass (including 2AA label)
10		0	1751.6240
11		0	1817.6228
12		0	2110.7822
13		-1	2026.7404
		-1	2032.7404
14		-1	2026.7404
15		-1	2032.7404
16		-1	2106.7982
17		-1	2401.8376

Anion-Exchange Separation of Native *N*-Glycans from Fetuin


Column: Dionex CarboPac PA200
 Dimensions: 250 mm × 3 mm i.d.
 Eluent: A. 100 mmol/L NaOH
 B. 0.25 mol/L NaOAc in 100 mmol/L NaOH
 Flow rate: 0.5 mL/min
 Injection: 500 pmoles
 Detection: IPAD, Au electrode
 Sample: Native *N*-glycan from bovine fetuin




Time (min)	% A	% B	Flow rate (mL/min)
-10	90	10	0.5
0	90	10	0.5
60	40	60	0.5
61	0	100	0.5
67	0	100	0.5
68	90	10	0.5

Labeled Glycans

- High throughput
- Early discovery



Workflow



Hands-on time < 3 h



Time to results: 7 – 9 h* (96 samples)

*Depends on the dye used for glycan labeling




Applied Biosystems® 3500 XL Genetic Analyzer

- Industry „gold standard“ CE instrument
- Parallel analysis of 8 or 24 samples in 45 min
- Multi-color capability
- Calibration across capillaries using internal standard
- RFID-tagged capillary array & CE consumables for automated tracking




24 Capillary Array (60 cm)

Glycopeptides



Glycopeptide Workflow




- Important for site profiling of PTMs including glycosylation
 - A variety of fragmentation techniques can be used
 - **ETD, HCD** or CID
- **Robustly digest in 1 h** using Thermo Scientific™ SMART Digest™ kits
- Bioinformatics tools are extremely valuable for data interpretation and glycosite profiling
 - Thermo Scientific™ BioPharma Finder™ software


Complete Characterization of Glycopeptides Using HCD and ETD



- Unique HCDpdETD method features on-the-fly identification of glycopeptides using diagnostic fragment ions from carbohydrate fragmentation.
- A high quality HCD spectrum is generated for each peptide.
- An additional ETD spectrum is generated for each glycopeptide.
- For each glycopeptide, ETD provides information of peptide sequence and site of glycosylation while HCD provides information of glycan structure and additional peptide sequence.




ETD Fragmentation
HCD Fragmentation



Zhiqi Hao et al. 2014 ASMS TP264

Unlabeled *N*-Linked Glycans



Charged Aerosol Detection for Unlabeled Glycans




Glycoprotein

Glycosidase



Released Glycans



- No requirement for labeling
- Near-universal detection
- Quantitative response without individual standards
- Orthogonal detection to MS




Released 2015

**Thermo Scientific™
Vanquish™ charged
Aerosol detector**

Full integration with Thermo Scientific™ Vanquish™ UHPLC platform, slide-in module design, reduced flow path for optimum operation


Label-Free Analysis of N-linked Glycans by UHPLC-CAD



System: Vanquish UHPLC
Column: GlycanPac AXR-1, 1.9 μ m
Dimensions: 150 m \times 2.1 mm i.d.
Temperature: 30°C
Eluent: A. Deionized water
B. 100 mmol/L ammonium formate, pH 4.4
Gradient: 4–39 % B in 35 min
Flow rate: 0.4 mL/min
Inj. volume: 2 μ L
Detection: Charged Aerosol Detection (50°C, PF 1.0, 10 Hz, 5 s)

PNGase F Digest – No Labeling Required

HPAE-PAD of N-Linked Oligosaccharides from IgG and a mAb





Common N-linked Oligosaccharides Found on IgG

- N-acetylglucosamine (GlcNAc)
- ▲ Fucose (Fuc)
- Mannose (Man)
- Galactose (Gal)
- ◆ N-acetylneuraminic acid (Neu5Ac)


Glycan (Oxford)	mAb acronym	Structure
NGA2F (FA2G0)	G0F	
NA2G1F (FA2G1)	G1F	
NA2F (FAG2)	G2F	
NA2FB (FABG2)	G2bF	
G2FA1 (FA2G2S1)	A1F	
G2FA2 (FAG2S2)	A2F	
NGA2 (A2G0)	G0	
Man3	M3	
Man5	M5	
Man6	M6	

Label-Free Analysis of N-linked Glycans by HPAE-PAD-MS



HPAE-PAD is able to separate highly complex glycan mixtures based on charge, linkage & fucose

Intact Glycoprotein



Intact Glycoform Workflow



Protein or reduced protein




UHPLC Orbitrap MS


- **Fast analysis** of the protein in “intact” form is important for biotherapeutic development
- A legal requirement to characterize the intact form and determine heterogeneity
- Due to the variations in structure, charge, etc. Of the attached glycans, the highest resolution and most accurate mass MS is required for precise quantification.

Glycan Analysis of Rituximab


(A)




(B)



(C)



(D)



Man5/G1

Man5/G0

(Man5)₂

G0/G0F

G0F/G0F

G0F/G1F

G0F/G2F or (G1F)₂

G1F/G2F

G2F/G2F

(G1F/G2F)SA1

(G2F/G2F)SA1

(G1F/G2F)SA2


(G2F/G2F)SA2









Application Note 21465: Fast online desalting of mAbs using a reversed-phase desalting cartridge for LC-MS analysis

Intact Glycoprotein Characterization

- A **fast 4 min** desalting method for high-throughput characterization
- Intact Mab mass and the relative **glycoform abundance within 5 min**
- In-depth characterization for glycoforms detection **below 1% relative intensity**
- Single software for all data processing
 - BioPharma Finder software



Summary – Glycan Workflows



Thank You for Your Kind Attention

